CompletedNot Applicable

Relaxin and Placental Volume in Placenta Accreta Spectrum

Turkey (Türkiye)40 participantsStarted 2022-01-01

Plain-language summary

This retrospective case-control study investigated the potential role of circulating relaxin levels and estimated placental volumes (EPV) in the pathogenesis and diagnosis of placenta accreta spectrum (PAS) disorders. It compared these parameters in patients diagnosed with PAS versus healthy controls.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Women aged 18-45 years Confirmed histopathological diagnosis of PAS (case group) Complete medical records Healthy pregnant women undergoing cesarean delivery (control group) Exclusion Criteria: Multifetal gestation Emergency surgeries Incomplete medical records

What they're measuring

Circulating relaxin (RLN2) levels in peripheral and umbilical cord blood

Timeframe: 11 months

Trial details

NCT IDNCT06808165

SponsorBaşakşehir Çam & Sakura City Hospital

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2022-11-01

View on ClinicalTrials.gov More Placenta Accreta Spectrum trials